The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Aminophylline Injection, USP

Vial NDC	Carton NDC	Lot Number	Expiration Date	Description	Configuration/Count
0409-5921-16	0409-5921-01	30-137-DK	1-DEC-2022	250 mg/10mL (25 mg/mL) Single-Dose Vial	2 X 25, 10 mL Fill in 20 mL Fliptop Vials

Hospira Inc., a Pfizer company, is recalling the above-referenced lot of **Aminophylline Injection, USP**, to the **User level**, due to a confirmed report of a visible particulate observed in a single vial**.** Pfizer completed a Health Hazard Assessment which concluded that the use of the impacted product has an unlikely probability of being associated with limited adverse events such as end-organ granuloma or tissue ischemia, tissue inflammation or phlebitis, decreased blood flow to the brain, heart attack, tissue necrosis, hypersensitivity reactions and infections. The overall potential risk to patients arising from this issue is considered to be low. The affected lot was distributed between **October 25, 2021 through April 01, 2022.**